Constitutional SMARCB1 mutations at 22q11.23 have been found in ~50% of familial and <10% of sporadic schwannomatosis cases 1 . We sequenced highly conserved regions along 22q from eight individuals with schwannomatosis whose schwannomas involved somatic loss of one copy of 22q, encompassing SMARCB1 and NF2, with a different somatic mutation of the other NF2 allele in every schwannoma but no mutation of the remaining SMARCB1 allele in blood and tumor samples. LZTR1 germline mutations were identified in seven of the eight cases. LZTR1 sequencing in 12 further cases with the same molecular signature identified 9 additional germline mutations. Loss of heterozygosity with retention of an LZTR1 mutation was present in all 25 schwannomas studied. Mutations segregated with disease in all available affected first-degree relatives, although four asymptomatic parents also carried an LZTR1 mutation. Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ~80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1.
Constitutional SMARCB1 mutations at 22q11.23 have been found in ~50% of familial and <10% of sporadic schwannomatosis cases 1 . We sequenced highly conserved regions along 22q from eight individuals with schwannomatosis whose schwannomas involved somatic loss of one copy of 22q, encompassing SMARCB1 and NF2, with a different somatic mutation of the other NF2 allele in every schwannoma but no mutation of the remaining SMARCB1 allele in blood and tumor samples. LZTR1 germline mutations were identified in seven of the eight cases. LZTR1 sequencing in 12 further cases with the same molecular signature identified 9 additional germline mutations. Loss of heterozygosity with retention of an LZTR1 mutation was present in all 25 schwannomas studied. Mutations segregated with disease in all available affected first-degree relatives, although four asymptomatic parents also carried an LZTR1 mutation. Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ~80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1.
Schwannomatosis (MIM 162091), the third major form of neuro fibromatosis, is a lateonset tumor predisposition disorder that is clinically and genetically distinct from neurofibromatosis types 1 (MIM 162200) and 2 (MIM 101000). Although isolated schwanno mas are common benign tumors, schwannomatosis-characterized by the development of multiple schwannomas without the bilateral ves tibular schwannomas, congenital cataracts or ependymomas typically associated with neurofibromatosis type 2-is rare; however, its exact incidence is unknown 2, 3 . While constitutional NF2 mutations are not found, independent somatic mutations affecting both NF2 alleles are typically present in every schwannoma of individuals with schwanno matosis 4 . Multipoint linkage analysis in families with schwannomatosis pointed to an ~8.48Mb region centromeric to the NF2 locus, between markers D22S420 and D22S1148, as the linked region 5 . Germline mutations in SMARCB1, located in this region and previously known to cause rhabdoid tumor predisposition syndrome (RTPS), have since been found in schwannomatosis cases 2, [6] [7] [8] [9] [10] . Genetic analysis of schwannomas in cases with a SMARCB1 germline mutation (first event, E1) shows loss of a region at 22q (second event, E2), with retention of the SMARCB1 mutation in the schwannomas, followed by mutation of the remaining wildtype NF2 gene (third event, E3) in cis with the SMARCB1 germline mutation 2, 7 . These three events result in biallelic loss of both the SMARCB1 and NF2 tumor suppressor genes in the schwannomas.
As germline SMARCB1 mutations account for only ~50% of familial and <10% of sporadic cases 11 , additional schwannomatosis predisposing loci probably exist. A subset of cases had no constitu tional firsthit SMARCB1 mutation but had deletion of part of 22q encompassing both NF2 and SMARCB1 and somatic mutation of the remaining NF2 allele in the schwannomas (Online Methods and Supplementary Fig. 1 ). We hypothesized that either functionally important sequences outside of the SMARCB1 regions previously analyzed through clinical testing (for example, introns, 5′ or 3′ UTRs or intergenic regions) or an alternative evolutionarily conserved locus on chromosome 22 might carry a first hit predisposing to Germline lossoffunction mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas schwannomatosis in these cases. Here we report studies of germ line DNA in 20 unrelated probands (6 familial cases, 11 sporadic cases and 3 cases with unknown family history of schwannomatosis; Supplementary Table 1) with an unknown firsthit mutation in blood and schwannomas (E1?), loss of 22q (E2 + ) and a different NF2 mutation in every schwannoma (E3 + ) (Supplementary Fig. 1 ). We selectively enriched for 3.72 Mb of highly conserved sequence along chromosome 22 and initially performed deep parallel sequenc ing in eight cases (NGS1-NGS8) ( Supplementary  Fig. 2 and Supplementary Tables 3 and 4a) . Manual examination of intronic LZTR1 sequences identified mutations affecting conserved splice sites in three additional probands of this initial cohort; these mutations included c.264-13G>A, c.1449+1G>A and c.2220-16_2220-14delCTT (Supplementary Fig. 3 ). All mutations were confirmed by Sanger sequencing. Analysis of discrepancies in insert size and anomalies in mapping information did not identify likely pathogenic intrachromo somal changes (Online Methods and Supplementary Table 5) .
Sanger sequencing of LZTR1 in lymphocyte DNA from 12 fur ther unrelated E1?E2 + E3 + probands (S1-S12) identified additional mutations in 9 cases ( Fig. 1 and Table 1 ). In total, 15 different previ ously unreported germline mutations in LZTR1 were found in 16 of 20 unrelated schwannomatosis probands negative for SMARCB1 mutation (E1?E2 + E3 + ) but in 0 of 8 schwannomatosis probands pos itive for SMARCB1 mutation (E1 + E2 + E3 + ) (P = 0.0002, twotailed Fig. 3 ). d A recurrent mutation found in two unrelated cases. e Likely pathogenic mutation affecting the highly evolutionarily conserved CTT nucleotide motif within the splice acceptor of exon 19: phastCons score of 1.00 and phyloP score for the consecutive nucleotides of 2.87, 2.95 and 2.14. f The c.594-3C>T transition is annotated in ESP but is predicted not to affect splicing, whereas the c.594-3C>G transversion has not previously been reported. c.594-3C>G is predicted to create a novel splice acceptor sequence and to decrease the strength of the wild-type splice acceptor site, and it was proven in this study to cause aberrant splicing (skipping of exon 7) at the mRNA (cDNA) level. g c.2348C>T is a SNP (rs143507674) at chr. 22: 21,351,197 in dbSNP137; however, no pathogenic c.2348_2351delCGCA is present in dbSNP137 or ESP.
l e t t e r s npg l e t t e r s
Fisher's exact test; Supplementary Table 6), including 6 truncating mutations (4 frameshift and 2 outofframe splicesite mutations), 1 inframe splicesite mutation, a 3nt deletion affecting a highly evolutionarily conserved splice acceptor sequence and 7 different missense mutations predicted to be damaging, all of which were absent in dbSNP137, the 1000 Genomes Project and ESP6500 (Fig. 1 13 . LZTR1 is expressed ubiquitously and abundantly in human tissues 13, 14 . LZTR1 resides centromeric to SMARCB1, also within the previously identified schwannomatosis associated linkage interval 5 . Loss of heterozygosity with retention of the casespecific LZTR1 mutation was found in all 25 schwannomas studied, strongly supporting the hypothesis that the LZTR1 mutations are pathogenic (the likelihood of such genetic changes occurring by chance in all 25 tumors in 16 unrelated cases is conservatively ~1. 
Exon 11 c.1210G>A p.Gly404Arg npg l e t t e r s with the presence of multiple schwannomas in all seven affected firstdegree relatives from five families, in line with autosomal domi nant inheritance (Fig. 3) . A germline LZTR1 mutation was identified in all familial cases studied and in 8 of 11 reportedly sporadic cases. No firsthit LZTR1 mutations were detected in the schwannomas of the remain ing three sporadic cases; therefore, LZTR1 mosaicism is unlikely to explain the phenotype of these individuals (Supplementary Table 6 ).
The clinically unaffected fathers of four reportedly sporadic cases carried the familial LZTR1 mutation (Fig. 3) , probably demonstrat ing nonpenetrance, which has previously been observed in familial schwannomatosis pedigrees 9 . As these individuals did not undergo full body magnetic resonance imaging (MRI), they may carry unrecognized tumors. It is possible that LZTR1 mutations predispose to a phenotype at the mild end of the spectrum (even resulting in a single schwannoma, which is a common finding in the general population) with incomplete penetrance; larger studies including more affected individuals and their unaffected relatives will help resolve this question.
LZTR1 was recently characterized as a tumor suppressor gene and driver in glioblastoma multiforme (GBM) on the basis of the presence of biallelic mutations in 4 of 139 GBM samples, with muta tions driving selfrenewal and growth of glioma spheres 15 . Moreover, somatic LZTR1 mutations have been identified in several cancers (Catalogue of Somatic Mutations in Cancer (COSMIC) database) ( Supplementary Table 4b ). However, some lossoffunction muta tions in LZTR1 have also been found in control populations (ESP2500 and the 1000 Genomes Project), a feature shared with some other tumor suppressor genes involved in hereditary predisposition to lateonset disorders, including MSH6, PMS2, BRCA1 and BRCA2. All these genes have a complex spectrum of mutations associated with variable expressivity and penetrance [16] [17] [18] , and, for BRCA2, MSH6 and PMS2, biallelic mutations have been found in rare individuals with distinct phenotypes 19 . Penetrance for associated tumors may be dif ferent for a given gene and even may be different depending on the specific mutation.
We performed a detailed analysis of the spectrum and frequency of LZTR1 mutations in tumor databases (schwannomatosis, GBM and the confirmed somatic cohort in COSMIC) versus control data bases (ESP2500 and the 1000 Genomes Project) ( Supplementary  Figs. 6 and 7 and Supplementary Tables 3 and 4) . The frequencies of predicted pathogenic mutations in LZTR1 in cases from the present study (16/20) and controls (27/3,292) were extremely statistically dif ferent (P < 0.0001; 2tailed Fisher's exact test). In addition, the differ ence in the predicted pathogenicity of observed missense mutations in the tumor databases (schwannomatosis, GBM and the confirmed somatic cohort of COSMIC) and control databases was also very sta tistically significant. The frequency of different/nonrecurrent pre dicted damaging missense mutations in the tumorassociated cohorts (25/35) versus control populations (12/34) was also very statistically significant (P = 0.0037, 2tailed Fisher's exact test; Supplementary  Fig. 6 ). None of the mutations in the tumor databases were present in the control databases, except for the mutation encoding a p.Phe447Leu alteration from COSMIC, which was predicted to be probably benign. Of the 35 different missense mutations reported in the tumorassociated data sets, 10 were found in >1 unrelated tumor sample or were affecting a critical amino acid (Arg68) observed to be targeted by different codonchanging mutations, implying functional significance. Nevertheless, the available data from control cohorts suggest that pathogenic mutations in the LZTR1 tumor suppressor gene are observed in presumably asymptomatic cases, and further studies in individuals heterozygous or compound heterozygous for such mutations will allow a better understanding of the spectrum of phenotypes associated with mutations in this gene.
The LZTR1 protein belongs to a functionally diverse superfamily of BTB/POZ (bricabrac, tramtrack and broad complex/pox virus and zincfinger) proteins 20 . The LZTR1 domain arrangement is unique compared to all other known BBK proteins (NBTBBACK (BTB and Cterminal Kelch)KelchC) 21 and contains an Nterminal Kelch domain with six Kelch motifs followed by two BTB domains (Fig. 2) . Following each BTB domain, a partial BACK domain (NKelchBTB BACK(p)BTBBACK(p)C) is predicted (Supplementary Fig. 8 ) 22 , which may be important to position the Kelch domains for substrate recognition 23 . All seven missense mutations and the inframe splice site mutation c.1449+1G>A (encoding p.Glu453_Lys484del) affect Figure 3 Pedigrees of families positive for LZTR1 mutation with information from relatives available for testing. Filled symbols represent individuals clinically affected by schwannomatosis. Open symbols with a vertical line represent clinically asymptomatic, (likely) non-penetrant individuals carrying the familial LZTR1 mutation. Plus and minus signs indicate individuals positive or negative for the family-specific mutation, respectively. LZTR1 mutation in probands (arrows) was initially identified by next-generation sequencing of evolutionarily conserved sequences at 22q (NGS2, NGS3, NGS5, NGS7) or by sequencing the entire coding sequence of the LZTR1 gene and flanking intronic sequences (S1, S3, S6, S7, S9). Relatives were subjected to targeted analysis of the family-specific LZTR1 mutation identified in the proband.
npg l e t t e r s highly evolutionarily conserved residues within functional domains of importance and are therefore predicted to be pathogenic (Figs. 1  and 2 and Supplementary Figs. 2 and 8-11) .
BTBcontaining proteins control fundamental cellular processes, ranging from the regulation of chromatin conformation to the cell cycle. Alterations in their activities have been linked to many inher ited diseases and cancers (Supplementary Fig. 9 ) 24, 25 . They share a role as substrate adaptors for cullin3 (Cul3) RING ligase (CRL3), which recruits substratespecific adaptors to catalyze protein ubiqui tination 20 . Kelch domains are the most common substrate recognition domains for Cul3 (ref. 26) . A mass spectroscopy study inferred an association of LZTR1 and Cul3 (ref. 27) , which was recently proven by immunoprecipitation to specifically involve the BTB domain, as expected 15 . LZTR1 localizes to the Golgi network in endothelial, smooth muscle and HeLa cell lines, with this localization mediated by LZTR1-BTBII (ref. 21) , and it may stabilize the Golgi complex via interaction with other proteins 21, 28 . Other roles for both BTB domains need further study.
LZTR1 contains a bipartite nuclear localization signal, which may facilitate its transport to the nucleus, as shown for another BBK family member localized at the Golgi in nondividing cells and translocated to the spindle apparatus during mitosis 29 (Online Methods and Supplementary Fig. 12 ).
Several proteins containing BTB/POZ domains interact with the NCoR (nuclear receptor corepressors) and SMRT (silencing mediator for retinoid and thyroid receptors) nuclear receptor core pressors 30, 31 . The NCoR complex also contains components of the SWI/SNF chromatinremodeling complex, and SMARCB1 was previously proven to interact with NCoR, indicating a potential functional link between LZTR1 and SMARCB1 or other members of the SWI/SNF complex 32 . Moreover, studies in the evolutionarily distant organism Toxoplasma gondii have shown that the Toxoplasma homolog of LZTR1 interacts with SRCAP 33 , another member of the SWI/SNF complex.
SMARCB1 was previously shown to interact with HDAC4 (histone deacetylase 4) 34 , and mammalian twohybrid analysis has recently shown that LZTR1 also interacts with HDAC4 (ref. 35) . Furthermore, LZTR1 physically associates with STAT1 (signal transducer and activator of transcription 1) and PARP1 (poly (ADPribose) polymerase 1) 35 , both of which, through binding to the SMARCB1 promoter, are involved in the upstream regulation of SMARCB1 (refs. 36,37) . Histone deacetylase inhibitors are emerging as a new class of anti tumor drugs, and AR42, a novel compound with HDAC inhibitor activity, was recently shown to inhibit growth in schwannoma and meningioma cells, offering the prospect of its further evaluation as a potential treatment in schwannomatosis 38 .
Further in vivo and in vitro studies are needed to unravel the pre dicted tissuespecific functions of the different LZTR1 isoforms, their cellular localization and the proteins with which they interact in order to understand the mechanisms contributing to the pathogenesis of schwannomas and other tumors. In conclusion, we report the dis covery of germline LZTR1 mutations whose frequency in individuals with schwannomatosis versus controls, retention in all studied schwannomas, segregation within affected families and predicted effects on protein function provide robust evidence that they are dis ease predisposing. 
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AUtHOR CONtRIBUtIONS
ONLINe MethOds
Cases and clinical data. All probands were diagnosed with either sporadic or familial schwannomatosis on the basis of diagnostic guidelines and were previ ously referred for genetic testing at the University of Alabama at Birmingham Medical Genomics Laboratory. The cohort of 20 probands studied here is a subpopulation of all schwannomatosis cases referred for genetic testing.
Through comprehensive mutational analyses of NF2, SMARCB1 and copy number changes at 22q in schwannomas and blood from schwannomatosis cases, we have identified five main groups of affected individuals:
(1) E1 + E2 + E3 + : cases carrying a SMARCB1 firsthit mutation in blood and schwannomas (positive (+) for mutational event 1, E1 + ), with loss of 22q (encompassing the region between and including LZTR1 and CABP7) in the schwannomas (E2 + ) and a different NF2 mutation in each schwannoma (E3 + ), resulting in biallelic loss of SMARCB1 and NF2. (2) E1?E2 + E3 + : cases with no SMARCB1 firsthit mutation detectable in blood and schwannomas, although they still have loss of a region at 22q (encompassing the region between and including LZTR1 and CABP7) in the schwannomas and a different NF2 mutation in each schwannoma. In the schwannomas both positive and negative for SMARCB1 mutation with loss of 22q and a different NF2 mutation in each schwannoma, the eventual (ultimate) target was inactivation of both NF2 copies. It is pos sible that the undetected firsthit mutations affect functionally important sequences outside the SMARCB1 coding region, such as the 5′ or 3′ UTR or a conserved intronic or intergenic region (that may not typically be part of the clinical testing that focuses on sequencing of the exons and their flanking intron sequence as well as on copy number analysis) or that an alternative gene on chromosome 22 carries the first predisposing hit (first event, first hit) in these cases. (3) E1?E2 + E3?: cases with no SMARCB1 firsthit mutation detectable in blood and schwannomas, although they still have loss of a region at 22q (encompassing SMARCB1 and NF2) in the schwannomas but no muta tions identified in the NF2 gene. (4) E1?E2 − E3?: cases with no SMARCB1 firsthit mutation detectable in blood and schwannomas, no loss at 22q and no identified NF2 muta tions. This group of cases may be a heterogeneous population, where the underlying genetic cause may be diverse and is more likely to be unrelated to chromosome 22. (5) Some cases were additionally identified as being mosaic NF2 mutation carriers, with the presence of a common firsthit NF2 mutation in their schwannomas (see the cautionary note on diagnostic criteria in Plotkin et al. 2 ). In addition, for some cases, only blood was available for testing, and no germline SMARCB1 or NF2 mutation was detected; therefore, genetic analysis did not allow us to molecularly confirm suspected diagnosis.
All 20 probands in the current study had previously undergone clinical genetic testing for SMARCB1 and NF2 mutations at the University of Alabama at Birmingham Medical Genomics Laboratory on blood and tumor sam ples and belonged to group 2 (E1?E2 + E3 + ). The study was approved by the institutional review board at the University of Alabama at Birmingham, and informed consent was obtained from all subjects. Clinical data are summa rized in Supplementary Table 1 . Mutational data are summarized in Figure 1 , Table 1 , Supplementary Figures 1 and 13 , and Supplementary Table 7 .
Targeted resequencing of chromosome 22. A custom SureSelect target enrich ment library (design ID 0371891) was designed using the SureDesign online tool (Agilent Technologies). Briefly, the custom enrichment library targeted exonic and noncoding evolutionarily conserved elements (conserved in verte brates with PhastCons scores of >0.85) within previously defined linkage inter vals as well as other conserved regions along 22q. The library also included the entire repeatmasked genomic sequence of the SMARCB1, NF2 and CABIN1 genes, previously implied (SMARCB1 and NF2) or suggested (CABIN1) to be important in schwannomatosis [39] [40] [41] [42] . In total, the library covered 3.72 Mb of genomic reference sequence along 22q. Target capture was carried out accord ing to the manufacturer's protocol (Agilent Technologies). Samples were subjected to pairedend sequencing on an Illumina HiSeq 2000 instrument.
Corresponding data files have been deposited in ArrayExpress (accession EMTAB1574). Sequencing statistics are provided in Supplementary Table 2 . Sequencing reads were aligned to the human reference genome (hg19) using the BurrowsWheeler transform Aligner (BWA) 43 . Unmapped reads and reads with mapping quality of <30 (Phred scaled) were removed using SAMtools 44 . Structural variant analysis. Sorted and indexed BAM files were preprocessed with the BAM_preprocessingPairs.pl script from SVDetect r.0. 8 (ref. 12) . This script filters out correctly mapped reads and outputs anomalously mapped reads for downstream analysis. SVDetect was run on the output files with the following parameters: sliding window size for partitioning the genome for intrachromosomal rearrangements, µ + 2σ (where µ is the mean of the insert size distribution and σ is the standard error of the insert size distribution); length of the sliding window step, onefourth of the window size; minimum number of pairs in a cluster, onefourth of the median depth of coverage for the experiment; minimum number of σfold for insert size filtering and to call insertions, deletions or tandem duplications, 3; minimal final filtering score for calling structural variants, 0.8.
cDNA-based mutation analysis. cDNAbased analysis of the SMARCB1, NF2 and LZTR1 genes began with RNA extraction from a phytohemagglutininstimulated shortterm lymphocyte culture (STLC) and RTPCR using SuperScript II Reverse Transcriptase (Invitrogen by Life Technologies, 18064014).
cDNA regions were amplified using TakaRa Ex Taq (TAKARA BIO, RR001A) for SMARCB1 and NF2 and the Expand LongTemplate PCR sys tem (Roche Applied Science, 11681842001) for LZTR1. Direct shotgun Sanger sequencing of the entire coding regions was subsequently performed on an ABI PRISM 3730 Genetic Analyzer, and sequences were analyzed using SeqScape software v 2.5 (Applied Biosystem by Life Technologies) and mutation inter pretation software Alamut v.2.3 (Interactive Biosoftware). Primer sequences are available upon request.
To compensate for the location of the forward RTPCR primer in exons 1 of SMARCB1 and LZTR1 and the alternative transcripts affecting SMARCB1 exon 2 and LZTR1 exon 15, genomic DNA analysis of exons 1-3 of SMARCB1 and of exons 1 and 15 of LZTR1 was performed for each sample in parallel to RTPCR. All mutations found at the cDNA level were confirmed by analysis at the genomic DNA level.
Genomic DNA-based mutation analysis. Genomic DNA was amplified for all exons of the NF2, SMARCB1 and LZTR1 genes and for part of the 3′ UTR of the SMARCB1 and LZTR1 genes from peripheral blood leukocyte samples and fresh or formalinfixed paraffinembedded tumor tissues. SMARCB1 and LZTR1 amplicons were generated using LightScanner Master Mix (Idaho Technology, HRLSASY0003), and NF2 amplicons were generated using the Platinum Taq DNA Polymerase kit (Invitrogen by Life Technologies, 10966034).
PCR runs for all LZTR1 exons and for exons 1 of SMARCB1 and NF2 con tained DMSO to a final concentration of 5%. All primers were tagged with M13 to facilitate downstream sequencing (primer sequences available upon request). PCR products were sequenced bidirectionally on an ABI PRISM 3130xl or 3730 Genetic Analyzer, and sequences were analyzed using SeqScape software v2.5 and the mutation interpretation software Alamut.
Comprehensive analysis of schwannomas included sequencing of all SMARCB1 and NF2 exons and flanking intronic sequences (at least from −20 to +15 bp relative to the exon boundaries). LZTR1 mutations identified in blood were confirmed in tumors by targeted sequencing of the corresponding exonic or intronic region. Family studies were conducted on genomic DNA extracted from the saliva or blood (if available) of relatives by targeted analysis of the familyspecific LZTR1 mutation identified in the proband.
Multiplex ligation-dependent probe amplification. To detect copy number changes (deletions or duplications) of the NF2 and SMARCB1 loci and flank ing genes, genomic DNA extracted from blood leukocytes and schwannoma tumors was analyzed by multiplex ligationdependent probe amplification (MLPA) using the SALSA MLPA kit (MRCHolland, P044_B1, P258_C1) according to the manufacturer's suggestions. Notably, the SMARCB1 SALSA MLPA kit also contains a probe assessing LZTR1; therefore, a deletion or duplication encompassing this region would also be detected. Owing to the quality of the DNA extracted from formalinfixated paraffinembedded tissue, MLPA analysis was not of sufficient quality in some samples, and microsatellite marker analysis was therefore used to assess the loss of 22q in such cases.
Microsatellite marker analysis. Analysis of loss of heterozygosity for the region of chromosome 22 encompassing LZTR1, SMARCB1 and NF2 was analyzed using microsatellite markers as previously described 42 .
Predictions of the effects of missense mutations. Three software programs were used to predict the effects of missense mutations as previously described: PolyPhen 45 , SIFT 46 and MutationTaster 47 .
In addition, predictions were generated on the basis of sequence align ment, secondary structure prediction, molecular modeling and residue per mutation. All sequences were obtained from Ensembl. Conserved domains were searched against the CDDv3.0843334 PSSMs (PositionSpecific Score Matrices) and SMART v6.01013 PSSMs databases, through the NCBI web site [48] [49] [50] . The Protein Homology/analogY Recognition Engine (Phyre) was used for secondary structure prediction 51 . SWISSMODEL (automated mode) was applied for homology modeling [52] [53] [54] . Homology models used included the crystal structure of the Kelch domain of human Keap1 (Protein Data Bank (PDB) 1U6D), the crystal structure of the SPOP BTB domain complexed with the Cul3 Nterminal domain (PDB 4EOZ) 55, 56 and the solution structure of the BACK domain of Kelch repeat-and BTB domain-containing protein 4 (PDB 2EQX). Residue permutation and illustrations were generated with PyMOL (DeLano Scientific, PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger).
Predictions of nuclear localization signal and subcellular localization. LZTR1 nuclear localization signal was predicted with MyHits Motif Scan 57 and through PSORT II prediction 58 . LZTR1 subcellular localization was pre dicted with WoLF PSORT 59 .
Analysis of variants from ESP6500, ESP2500, the 1000 Genomes Project, dbSNP and COSMIC. All LZTR1 variants were downloaded from the ESP6500 database. Although this database was very useful in establishing the absence of any given mutation found in our cohort, it was less useful in evaluating the significance of rare LZTR1 variants, mainly because of a lack of largescale validation of the variants. In general, indel calls were less robust than SNP calls and had a higher false positive rate. After review of the data, 12 possible lossoffunction mutations (9 mutations with a single occurrence, 1 mutation occurring twice and 2 recurrent mutations) were identified, 6 of which were indels. Five of the six indels affected homopolymer runs, which are known to be prone to artifacts. We have specifically investigated the two recurrent indel mutations present in ESP6500 (c.21del1 (allele count A1 = 66, R = 11,900; genotype count: A1/A1 = 7, A1/R = 52, R/R = 5,924) and c.1506_1507insG (allele count A1 = 143, R = 11,227; genotype count: A1/A1 = 17, A1/R = 109, R/R = 5,559) (where R is the reference allele), which both had genotype counts deviating from HardyWeinberg equilibri)um. We screened a large set of anonymous control samples (previously submitted for Fragile X testing and found to be negative for the presence of FMR1 intermediate alleles, premuta tion or full mutation and for the presence of the two recurrent frameshift indels c.21delG and c.1506_1507insG). These indels, respectively, were present in none of the 981 and 572 control individuals (c.21del1 (allele count A1 = 0, R = 1,962; genotype count: A1/A1 = 0, A1/R = 0, R/R = 981; twotailed P value = 0.0018 using χ 2 with Yates' correction) and c.1506_1507insG (allele count A1 = 0, R = 1,144; genotype count: A1/A1 = 0, A1/R = 0, R/R = 572; twotailed P value = 0.0002 using χ 2 with Yates' correction). These results are extremely statistically significant.
After we had proven that indel calls were less robust and represented false discovery data points, we used NHLBI ESP2500 and 1000 Genomes Project data as a point of reference for the assessment of LZTR1 variation in controls, as ESP2500 and 1000 Genomes Project data were obtained after applying more stringent filter criteria.
For the ESP2500 data, variants have been deposited in dbSNP (local batch ESP2500) by NHLBI ESP. From dbSNP138, we downloaded all the ESP2500 data by batch query of ESP2500 (ref. 60) . However, on the basis of dbSNP entries, none of the LZTR1 ESP2500 data have been confirmed independ ently using a different method (such as Sanger sequencing), but all calls were obtained after more stringent filtering criteria were applied.
For the 1000 Genomes Project database, Phase 1 variants were extracted with the UCSC Table Browser from Overall data in COSMIC include both mutations that are confirmed to be somatic and are therefore tumor specific and mutations whose somatic status is unknown (and where it is therefore unknown whether these mutations might be present in the germline). The overall spectrum of COSMIC LZTR1 muta tions consisted of 83 mutations: 1 nonsense, 62 missense (25 of 62 confirmed to be somatic), 16 synonymous, 3 frameshift and 3 splicesite mutations. We have specifically selected from the COSMIC database all mutations that were confirmed to be somatic for further analysis and comparison with vari ants from the other databases.
